Medigene announces market launch of Veregen® in Taiwan
01 10월 2013 - 2:30PM
Medigene AG / Medigene announces market launch of Veregen® in
Taiwan . Ad hoc announcement according to § 15 WpHG. Processed and
transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.
Martinsried/Munich, 1 October 2013. Medigene AG
(MDG, Frankfurt, Prime Standard) announced today that its partner
SynCore, a member of the Sinphar Pharmaceutical Group, has started
the launch of Veregen®, for the
treatment of genital warts, in Taiwan.
Dr. Frank
Mathias, Chief Executive Officer of Medigene AG, comments:
"We are glad to announce that Veregen® is launched
in the first country in Asia today. In cooperation with our partner
SynCore, we will step by step open up the Asian countries included
in our license agreement, and provide the patients in the growth
market Asia with our drug."
Veregen® is already
being marketed in the USA (by Fougera), in Germany, Austria and
Switzerland (by Abbott), in Spain (by Bial), in Serbia (by
Pharmanova) as well as in the Netherlands (by Will-Pharma) and
approved in further countries. Medigene expects the launch of
Veregen® in other
countries within the next few months. Medigene has entered into
numerous marketing partnerships for Veregen® across
Europe, Asia, and America, and is planning to continue this global
licensing strategy to further exploit the product's market
potential.
About
Veregen®:
Veregen®, a topical
treatment for external genital or perianal warts, contains a
concentrate of catechins with a complex defined composition
extracted from green tea leaves. In its current treatment
guidelines for sexually transmitted diseases, the US Center for
Disease Control and Prevention recommends Sinecatechins 15%
ointment (Veregen®) as a
possible option for treating genital warts. In addition,
Sinecatechins 10% & 15% ointment (Veregen®) has
been included in the current European guideline on the treatment of
genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
About
SynCore: SynCore Biotechnology Co., Ltd, a joint venture
between Sinphar Pharmaceutical Co., Ltd and the National Health
Research Institute of Taiwan, is focused on the development of new
drugs. Currently, SynCore has five products under development in
different stages of clinical trial. Additionally, SynCore has been
granted the exclusive development and marketing right in Asia for a
new drug for the treatment of dry AMD (age-related macular
degeneration) from MacuCLEAR, an US-based biotech company; the drug
received approval to enter into phase II/III clinical trial in the
US and Taiwan. For further information, please visit
www.syncorebio.com.
About
Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd
(Taiwan Stock Exchange, symbol: 1734), with subsidiaries in China
and Canada, specializes in the sales and marketing of
pharmaceutical products and dietary supplements as well as contract
manufacture for several global pharma companies such as Johnson
& Johnson, Takeda, Shionogi, and Astellas. Additionally,
Sinphar is one of the major producers of paclitaxel
(Phyxol®) in Asia. It
is also involved in the research and development of botanical new
drugs. Further information can be obtained at: www.sinphar.com.
Medigene
AG (Frankfurt: MDG, Prime Standard) is a publicly listed
biotech company headquartered in Martinsried/Munich, Germany.
Medigene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases. Medigene is the first
German biotech company to generate revenues from a marketed product
(Veregen®), which is
distributed by partner companies. Medigene also has two drug
candidates undergoing clinical trials, EndoTAG®-1 und
RhuDex®, and is
developing an innovative vaccine technology. For further details,
please visit www.medigene.com
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and Veregen® are registered trademarks of
Medigene AG. Polyphenon E® is a trademark of Mitsui
Norin Co., Ltd. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Medigene AG via Thomson Reuters ONE
HUG#1732444
Meridian Gold (NYSE:MDG)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Meridian Gold (NYSE:MDG)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
